MetaCap

Dermata Therapeutics (DRMA) vs Xenetic Biosciences (XBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.

Summary

Dermata Therapeutics is the larger company by market cap ($5.3 million vs $5.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Head-to-head

DRMA versus XBIO key metrics
MetricDRMAXBIO
Share price$1.07$2.12
Market cap$5.30M$4.97M
1-day change-4.46%-4.07%
EPS (TTM)$-4.39$-1.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$4.84$10.24
52-week low$0.951$1.87
Distance from 52-week high-77.89%-79.30%
Average volume708.18K87.71K
Shares outstanding4.96M2.34M
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

DRMA vs XBIO FAQ

Which is bigger, Dermata Therapeutics or Xenetic Biosciences?

Dermata Therapeutics (DRMA) is larger, with a market capitalization of $5.30M compared with $4.97M for Xenetic Biosciences (XBIO).

Are Dermata Therapeutics and Xenetic Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons